Multiple possible senolytic agents are under investigation.[3] Certain anti-cancer agents may in low doses decelerate aging and age-related diseases.[4] Targeting cancer prevention pathways with anti-cancer agents may confer longevity effects by offering protection from metabolic pathologies during aging, independently of effects on cancer.[5] Navitoclax, also known as ABT-263, was originally studied as an anti-cancer drug.[6]